# amicus-therapeutics

**Canonical:** https://apis.io/providers/amicus-therapeutics/  
**Website:** https://www.amicusrx.com  
**APIs profiled:** 0

Amicus Therapeutics is a global rare disease biotechnology company focused on discovering, developing, and commercializing medicines for people living with genetically defined conditions. Founded in 2002 and headquartered in Princeton, New Jersey, Amicus markets two approved therapies: Galafold (migalastat) — the first and only oral therapy for adults with Fabry disease who have an amenable GLA variant, approved by the European Commission in May 2016 — and the two-component Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat) enzyme replacement / stabilizer combination for adults with late-onset Pompe disease. Amicus operates wholly owned subsidiaries in Australia, Canada, France, Germany, Italy, Japan, the Netherlands, Spain, Switzerland, and the United Kingdom. BioMarin Pharmaceutical Inc. agreed to acquire Amicus in December 2025 for $4.8 billion; the acquisition completed on April 27, 2026 and Amicus now operates as a wholly owned subsidiary of BioMarin, having previously traded on NASDAQ under the ticker FOLD. The company maintains no publicly documented commercial developer APIs, SDKs, or GitHub organization; its digital surface is composed of corporate, product, patient-support, and clinical-trial websites.

## Kin Score — 9.5 / 100 (minimal)

Scored 2026-08-20 under rubric 0.12.0. Trend: flat (+0.0 from 9.5).

| Facet | Score |
|---|---|
| Discoverability | 44.4 |
| Contract Quality | 11.3 |
| Governance | 25.0 |
| Contract Governance | 25.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 0.0 |
| Commercial Clarity | 0.0 |
| Access Clarity | 0.0 |

Regulatory layer — **Health**: 13.8 (matched via tags).

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## Access

Unknown — onboarding: unknown, pricing: unknown, trial: no (confidence: low).

## Security (1)

- **Amicus Therapeutics Domain Security** — TLSv1.3 · HSTS · DMARC

## Tags

Biotechnology, Pharmaceuticals, Rare Diseases, Genetic Diseases, Fabry Disease, Pompe Disease, Lysosomal Storage Disorders, Enzyme Replacement Therapy, Pharmacological Chaperones, Clinical Research, Life Sciences, Patient Advocacy

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/amicus-therapeutics/). Scores are computed from the provider's own public artifacts under a published rubric.